Biogetica's groundbreaking trial on Herpes receives patent from the US Patent Office
Biogetica, has announced its groundbreaking trials result on Herpes, today. The research successfully marks reduced time & early treatment with the use of combination therapy of the company’s Hyperisince and Reginmune. The Ayurvedic remedy has been granted a patent by the US patent office.
In 2004, Dr. T Vijayan from the JSS School of pharmaceuticals discovered that extracts of Hypericum Mysorense, a rare plant from the Nilgiri Hills could completely suppress the herpes virus in-vitro. Hyperisince has since been licensed by AYUSH for the management of herpes and is slowly but surely gaining popularity amongst both Doctors and Patients looking for a safe and effective way of dealing with this pest of a virus variants of which are called herpes simplex and herpes zoster.
Speaking on the development, Dr. Vijay Kamat, Medical Director, Biogetica, said, “It is amazing to see how nature in its original perfection can outperform and complement synthetic molecules as medicine. This is a reality that both Doctors and Patients are waking up to globally. The old paradigm of patenting and mimicking molecules for profit is going away as the perfection of life cannot be recreated in a lab. We are forever grateful to Doctors across the planet that have helped us reach this point and those that realize that their Hippocratic oath is made to patient healing and not a particular medicine system.”
He further added that “We are successful, as each study we have conducted has shown groundbreaking results. We are failures as products such as hyperisince still yet do not sell even 1/10 of the pharmaceutical they outperformed in the studies. We keep going because each day we wake up to a letter of thanks from someone somewhere!”
Clinical trials published in 2017 showed remarkable results for Herpes, busting the age-old myth that Ayurveda takes a longer time to show results and that someone with herpes will always have recurrences. In the trial, it was seen that a herpes outbreak usually lasts 21 days without treatment. Acyclovir the FDA approved pharmaceutical for herpes can bring that duration down to 9 days. The combination therapy of Hyperisince and Reginmune however brought the average time down to 3 days. Furthermore, 76% of patients with genital herpes who took the combination of Hyperisince and Reginmune did not have a relapse of herpes for the follow-up period of 2 years.
The Indian Patent Office has published Patent Number 808/MUM/2013 for Biogetica’s proprietary formulation Hyperisince which combines Hypericum Mysorense with other Anti-Viral Herbs and has a unique cellular delivery mechanism. The US has published a patent number- 10,744,175, the document is attached for your reference.
